Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine–DMT Formulations
Anna C. Renner, Robert B. Kargbo
ACS Medicinal Chemistry Letters December 16, 2025 DOI: 10.1021/acsmedchemlett.5c00714 via OpenAlex
Summary
AI-generated from the abstractRecent inventions create a framework for safer, more reliable psychedelic medicines. Simplified iboga analogs offer tunable polypharmacology, real-time EEG biomarkers personalize psilocybin dosing, and standardized harmine-DMT ratios achieve high bioavailability. These innovations improve mechanistic precision, receptor selectivity, and pharmacokinetic control.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Electroencephalography Hallucinogen Investigational drugs Medicine |
| Key finding | Simplified iboga analogs, real-time EEG biomarkers for psilocybin dosing, and standardized harmine-DMT ratios together form a coherent framework for safer, more clinically actionable psychedelic medicines. |
Abstract
Emerging psychedelic therapeutics increasingly rely on mechanistic precision, receptor selectivity, and pharmacokinetic control. Recent inventions introduce simplified iboga analogs with tunable polypharmacology, real-time EEG biomarkers that individualize psilocybin dosing, and standardized harmine-DMT ratios with high bioavailability. Together, these innovations form a coherent framework for safer, more reliable, and clinically actionable psychedelic medicines.